Aprea Therapeutics shares surge 127.14% intraday after reporting early clinical proof-of-concept for APR-1051, including a partial response in endometrial cancer patient.

Aprea Therapeutics surged 127.14% intraday following the announcement of a clinical proof-of-concept in its ACESOT-1051 trial for WEE1 inhibitor APR-1051, including a 50% reduction in target lesion size and a 90% decrease in CA-125 levels in an endometrial cancer patient. The trial’s 150 mg dose demonstrated tolerability and disease stabilization, with the 220 mg cohort now enrolling. Concurrently, the company secured a $5.6 million private placement to fund patient enrollment and research, extending its cash runway. These developments, particularly the early clinical signals of efficacy, drove investor optimism about the drug’s potential, aligning with the stock’s sharp intraday rally.